- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- November 2024
- 50 Pages
Global
From €2589EUR$2,650USD£2,162GBP
- Report
- August 2024
- 225 Pages
China
From €3908EUR$4,000USD£3,263GBP
- Report
- August 2024
- 81 Pages
China
From €1759EUR$1,800USD£1,468GBP
- Report
- August 2024
- 91 Pages
China
From €1759EUR$1,800USD£1,468GBP
- Report
- March 2024
- 132 Pages
Global
From €928EUR$950USD£775GBP
- Book
- October 2021
- 168 Pages
- Report
- June 2019
- 15 Pages
Japan
€9771EUR$10,000USD£8,157GBP
- Report
- November 2023
- 35 Pages
Global
From €3605EUR$3,690USD£3,010GBP
The HIV/AIDS Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat HIV/AIDS. These drugs are used to treat the virus itself, as well as the symptoms and complications associated with it. HIV/AIDS drugs are typically divided into two categories: antiretroviral drugs, which are used to suppress the virus, and prophylactic drugs, which are used to prevent the transmission of the virus.
The HIV/AIDS Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Gilead Sciences, Merck, GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer. These companies are constantly developing new drugs and treatments to improve the quality of life for those living with HIV/AIDS. Show Less Read more